Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Axsome Therapeutics (AXSM) Accumulated Expenses (2022 - 2025)

Historic Accumulated Expenses for Axsome Therapeutics (AXSM) over the last 4 years, with Q3 2025 value amounting to $139.5 million.

  • Axsome Therapeutics' Accumulated Expenses rose 10281.97% to $139.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $139.5 million, marking a year-over-year increase of 10281.97%. This contributed to the annual value of $74.0 million for FY2024, which is 5831.14% up from last year.
  • According to the latest figures from Q3 2025, Axsome Therapeutics' Accumulated Expenses is $139.5 million, which was up 10281.97% from $118.2 million recorded in Q2 2025.
  • Over the past 5 years, Axsome Therapeutics' Accumulated Expenses peaked at $139.5 million during Q3 2025, and registered a low of $2.7 million during Q1 2022.
  • Its 4-year average for Accumulated Expenses is $54.2 million, with a median of $46.7 million in 2023.
  • Its Accumulated Expenses has fluctuated over the past 5 years, first surged by 101579.42% in 2023, then skyrocketed by 5831.14% in 2024.
  • Quarter analysis of 4 years shows Axsome Therapeutics' Accumulated Expenses stood at $26.5 million in 2022, then skyrocketed by 75.98% to $46.7 million in 2023, then soared by 58.31% to $74.0 million in 2024, then soared by 88.6% to $139.5 million in 2025.
  • Its Accumulated Expenses stands at $139.5 million for Q3 2025, versus $118.2 million for Q2 2025 and $95.8 million for Q1 2025.